#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study....
Boehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1 trial conducted in patients with obesity ...